Table 3.
Multivariate analysis of different prognostic factors in patients treated with regorafenib.
| Item | PFS |
OS |
||||
|---|---|---|---|---|---|---|
| P value | HR | 95% CI | P value | HR | 95% CI | |
| Gender (male vs female) | .6958 | 0.881 | 0.468-1.659 | .6265 | 1.195 | 0.583-2.453 |
| ECOG PS (1 vs >1) | .0097 | 2.683 | 1.270-5.668 | .0065 | 3.104 | 1.374-7.015 |
| Interval from metastasis to regorafenib (⩽1 y vs >1 y) | .9069 | 1.001 | 0.983-1.020 | .0517 | 1.019 | 1.000-1.039 |
| Sidedness (right vs left) | .3840 | 0.741 | 0.377-1.455 | .9111 | 0.958 | 0.453-2.027 |
| Number of organs involved (1 vs >1) | .5410 | 0.910 | 0.672-1.232 | .6957 | 1.062 | 0.785-1.439 |
| Regorafenib starting dose (160 vs <160 mg) | .8384 | 1.084 | 0.500-2.348 | .0716 | 2.244 | 0.931-5.406 |
| Dose reduction (yes vs no) | .1019 | 0.475 | 0.195-1.159 | .0704 | 0.357 | 0.117-1.090 |
Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Group Performance Status; HR, hazard ratio; OS, overall survival; PFS, progression-free survival.